Results 251 to 260 of about 409,524 (305)

Reply to Letter: “Limitations of Complement Activity Assays as Biomarkers for Ravulizumab Therapeutic Monitoring” by Saccà and Pelto Regarding “Inhibition of Classical and Alternative Complement Pathway by Ravulizumab and Eculizumab”

Annals of Clinical and Translational Neurology, EarlyView.
Lea Gerischer, Jutta Schroeder‐Braunstein, Guido Wabnitz, Andreas Meisel   +3 more
wiley   +1 more source

CD2AP is a disulfidptosis modulator and prognostic biomarker in hepatocellular carcinoma. [PDF]

Clin Exp Med
Tan Y, Yang L, Wang Q, Huang M, Yi B, Wan J, Xu T, Zhao Z, Tang C, Xie Y, Chen X, Tan W.   +11 more
europepmc   +1 more source

Monitoring immune cell dynamics for potential prognostic biomarker of sepsis. [PDF]

BMC Infect Dis
Ma H, Di J, Xiao S, Chen L, Zhao W, Cui J.   +5 more
europepmc   +1 more source

LRRC31 is a novel prognostic biomarker and therapeutic target for colorectal cancer. [PDF]

Discov Oncol
Xiu M, Yu Y, Wang X, Chen J.
europepmc   +1 more source

Integrated analysis reveals GSTA1 as a prognostic biomarker in stage I lung adenocarcinoma. [PDF]

BMC Cancer
Ren J, Zeng H, Zhang G, Ren F, Yuan Z, Huang Y, Xu J, Song Z, Li W, Ying J, Xue Q, Tan F.   +11 more
europepmc   +1 more source

Prognostic biomarkers in ovarian cancer [PDF]

Cancer Biomarkers, 2011
Epithelial ovarian cancer (EOC) remains the most lethal gynecological malignancy despite several~decades of progress in diagnosis and treatment. Taking advantage of the robust development of discovery and utility of prognostic biomarkers, clinicians and researchers are developing personalized and targeted treatment strategies.
Jie, Huang, Wei, Hu, Anil K, Sood
openaire   +2 more sources